Alpha memo: resveratrol / exercise bounded update

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reframe the alpha signal: the two receipts are not a contradiction or update pair but a cross-setting/cross-endpoint contrast. State explicitly that Receipt 1 (human, TMAO/CVD, older adults, 12-week exercise + 500/1000 mg resveratrol) and Receipt 2 (obese mice, weight loss/glucose/lipid/muscle, 4-week exercise + resveratrol) address different endpoints in different species and therefore do not directly falsify each other.
2. Remove the 'limited by Receipt 2' framing in the abstract and one-sentence alpha, or replace with a more accurate bounded contrast (e.g., 'human TMAO/cardiovascular signal in Receipt 1 is not corroborated by Receipt 2, which tests a different endpoint in obese mice').
3. Add a brief sentence in Synthesis noting the species and endpoint differences so the boundary signal is grounded rather than implied.
4. Adjust Caveats to acknowledge that the 'failure' read depends on assuming cross-endpoint/species equivalence, which the receipts do not establish.

Major issues

• The abstract states Receipt 1 'looks positive' but Receipt 2 'limits' it, implying a contradiction. Receipt 2's actual finding is that resveratrol+exercise did not add to body weight loss but improved glucose/lipid homeostasis and hepatic lipid — this is a different endpoint, not a limit on Receipt 1's TMAO/cardiovascular signal. The memo conflates 'different endpoint' with 'limiting evidence,' which is a falsification framing the sources do not support.
• The 'Why this is surprising' claim that 'the same named anchor is not enough' and the synthesis framing of Receipt 2 as the 'update receipt' imply Receipt 2 modifies Receipt 1. In fact the two receipts study different endpoints (TMAO/CVD risk vs. weight loss/glucose/lipid/muscle adaptation) in different species (humans vs. obese mice) — this is not an update, it is a different question.

Minor issues

• The alpha memo asks 'Does the positive signal in Receipt 1 hold in the setting tested by Receipt 2?' — but Receipt 2 does not test the same setting (different species, different endpoint), so the question is not actually answered by the pair; it is only reframed.
• Receipt 2 is framed as an 'update' but is also an older (2018) animal study vs. Receipt 1's 2024 human RCT — the temporal/logical relationship is inverted for an update framing.
• The 'Next test' recommendation ('one matched design') is reasonable but generic; specifying what endpoint, population, and species would strengthen it.

Reviewer note

The memo's structural intent — produce a bounded, source-grounded alpha signal from a two-receipt pair — is appropriate for the format, and the two cited sources do exist and match the bundle entries (DOI/cited_as cross-check passes). However, the central interpretive claim that Receipt 2 'limits' Receipt 1 is not supported by a direct reading of the receipts: they test different endpoints (TMAO/CVD metabolites vs. weight loss, glucose homeostasis, hepatic lipid, mitochondrial markers) in different species (older adults vs. obese mice) over different durations. The memo frames this as a falsification/update, when it is more accurately a cross-setting contrast. With a bounded edit to the framing in the abstract, one-sentence alpha, and Synthesis — clarifying that the receipts do not directly conflict but address different questions — the memo becomes a clean, honest boundary signal. Source grounding is good (both receipts are real, recent, and on-topic for resveratrol + exercise). Research question, limitations, and gaps are reasonable. Synthesis integration is adequate but undermined by the misframed contrast. Revise is appropriate; the manuscript is salvageable with bounded edits and does not require a scope reset.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis